Ernexa Therapeutics Inc. SEC filings ERNAW
Ernexa Therapeutics Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 3, 2010. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 30, 2026 | — |
| CORRESP | Letter to the SEC | Mar 26, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 20, 2026 | — |
| EFFECT | Filing | Feb 5, 2026 | — |
| CERT | Filing | Feb 5, 2026 | — |
| 8-A12B | Filing | Feb 5, 2026 | — |
| CORRESP | Letter to the SEC | Feb 3, 2026 | — |
| CORRESP | Letter to the SEC | Feb 3, 2026 | — |
| DRS | Filing | Oct 23, 2025 | — |
| DRSLTR | Filing | Oct 22, 2025 | — |
| EFFECT | Filing | Jun 18, 2025 | — |
| CORRESP | Letter to the SEC | Jun 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2025 | — |
| EFFECT | Filing | Apr 29, 2025 | — |
| CORRESP | Letter to the SEC | Apr 25, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2025 | — |
| D | Filing | Apr 11, 2025 | — |
| EFFECT | Filing | Nov 15, 2024 | — |
| D | Filing | Nov 14, 2024 | — |
| D | Filing | Nov 14, 2024 | — |
| CORRESP | Letter to the SEC | Nov 13, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2024 | — |
| EFFECT | Filing | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2024 | — |
| D | Filing | Dec 20, 2023 | — |
| EFFECT | Filing | Aug 22, 2023 | — |
| CORRESP | Letter to the SEC | Aug 18, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2023 | — |
| D | Filing | Jul 26, 2023 | — |
| D | Filing | Jul 26, 2023 | — |
| EFFECT | Filing | Apr 24, 2023 | — |
| CORRESP | Letter to the SEC | Apr 20, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2023 | — |
| EFFECT | Filing | Mar 20, 2023 | — |
| D | Filing | Dec 16, 2022 | — |
| NT 10-Q | Filing | May 17, 2022 | Mar 31, 2022 |
| EFFECT | Filing | May 11, 2022 | — |
| CORRESP | Letter to the SEC | May 9, 2022 | — |
| UPLOAD | Letter from the SEC | May 6, 2022 | — |
| NT 10-K | Filing | Apr 1, 2022 | Dec 31, 2021 |
| D | Filing | Mar 23, 2022 | — |
| EFFECT | Filing | Nov 26, 2021 | — |
| CORRESP | Letter to the SEC | Nov 23, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2021 | — |
| RW | Filing | Nov 18, 2021 | — |
| 8-A12B/A | 8-a12b | Nov 18, 2021 | — |
| CERT | Filing | Oct 22, 2021 | — |
| 8-A12B | Filing | Oct 22, 2021 | — |
| 25 | Filing | Oct 22, 2021 | — |
| EFFECT | Filing | Jun 4, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| CORRESP | Letter to the SEC | Jun 2, 2021 | — |
| EFFECT | Filing | May 10, 2021 | — |
| CORRESP | Letter to the SEC | May 6, 2021 | — |
| UPLOAD | Letter from the SEC | May 6, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 17, 2021 | — |
| 425 | Filing | Mar 8, 2021 | — |
| 425 | Filing | Feb 26, 2021 | — |
| 425 | Filing | Feb 25, 2021 | — |
| 425 | Filing | Feb 9, 2021 | — |
| 425 | Filing | Feb 4, 2021 | — |
| EFFECT | Filing | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Jan 19, 2021 | — |
| 425 | Filing | Jan 15, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 8, 2021 | — |
| CORRESP | Letter to the SEC | Dec 21, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 2, 2020 | — |
| CORRESP | Letter to the SEC | Nov 25, 2020 | — |
| 425 | Filing | Nov 23, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 2, 2020 | — |
| 425 | Filing | Sep 18, 2020 | — |
| 425 | Filing | Aug 14, 2020 | — |
| 425 | Filing | Aug 13, 2020 | — |
| SEC STAFF LETTER | Filing | Mar 6, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2020 | — |
| DEFR14A | Filing | May 21, 2019 | — |
| DEFR14A | Filing | May 9, 2019 | — |
| EFFECT | Filing | Feb 2, 2017 | — |
| CORRESP | Letter to the SEC | Jan 30, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2017 | — |
| CORRESP | Letter to the SEC | Jan 11, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2016 | — |
| CORRESP | Letter to the SEC | Apr 14, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2016 | — |
| EFFECT | Filing | Jan 9, 2014 | — |
| EFFECT | Filing | Dec 5, 2013 | — |
| D | Filing | Nov 18, 2013 | — |
| EFFECT | Filing | Jan 11, 2012 | — |
Showing 92 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERNA (Nasdaq), ERNAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc. (until Apr 4, 2025); Brooklyn ImmunoTherapeutics, Inc. (until Oct 14, 2022); NTN BUZZTIME INC (until Mar 23, 2021); NTN COMMUNICATIONS INC (until Dec 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.